8-K: Shuttle Pharmaceuticals Finalizes Clinical Trial Sites for Phase 2 Glioblastoma Study

Shuttle Pharmaceuticals has completed agreements with all six planned sites for its Phase 2 clinical trial of Ropidoxuridine for glioblastoma treatment.

Summary

• Shuttle Pharmaceuticals has finalized agreements with all six planned clinical trial sites for its Phase 2 study of Ropidoxuridine, a radiation sensitizer, for the treatment of glioblastoma.
• The six sites include Georgetown University Medical Center, UNC Medical Center, UVA Cancer Center, John Theurer Cancer Center, Allegheny Health Network Cancer Institute, and Miami Cancer Institute.
• Patients are currently being screened for enrollment in the trial.
• The Phase 2 trial will randomize 40 patients into two dose groups (20 at 1,200 mg/day and 20 at 960 mg/day) to determine the optimal dose.
• An additional 14 patients will be added at the optimal dose to reach the survival end-point for comparison to historical controls.
• The company expects the trial to be completed over the next 18 to 24 months.
• Ropidoxuridine has received Orphan Drug Designation from the FDA, which could provide marketing exclusivity upon approval.
• The company estimates that 800,000 patients in the U.S. are treated with radiation therapy annually, with 50% receiving it with curative intent, representing a market opportunity of 400,000 patients for radiation sensitizers.

Sentiment

Score: 7

Explanation: The document is positive, highlighting the progress of the clinical trial and the potential market opportunity. However, it also includes standard risk disclosures, which temper the overall sentiment.

Positives

• The company has successfully engaged all six planned clinical trial sites.
• Patient screening for the Phase 2 trial has commenced.
• Ropidoxuridine has received Orphan Drug Designation from the FDA, potentially providing marketing exclusivity.
• The trial is designed to determine an optimal dose of Ropidoxuridine for glioblastoma treatment.
• The company is targeting a significant market opportunity of 400,000 patients annually in the U.S.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The trial may not be completed within the expected 18 to 24 month timeframe.
• The trial may not demonstrate the efficacy of Ropidoxuridine as a radiation sensitizer.
• The company may not receive FDA approval for Ropidoxuridine.

Future Outlook

The company expects the Phase 2 clinical trial to be completed over the next 18 to 24 months and is focused on developing therapies to maximize the effectiveness of radiation therapy.

Management Comments

• We have successfully engaged all six of the planned clinical trial site locations to administer the Phase 2 clinical trial of Ropidoxuridine, commented Shuttle Pharmas CEO, Anatoly Dritschilo, M.D.
• The results of this trial will be important to the cancer community as we look for effective radiation sensitizers to increase cancer cure rates, prolong patient survival and improve quality of life for patients suffering from glioblastoma.

Industry Context

The announcement is relevant to the oncology and radiation therapy sectors, highlighting the ongoing efforts to improve cancer treatment outcomes through radiation sensitizers. The company is targeting a significant unmet need in glioblastoma treatment.

Comparison to Industry Standards

• The company's focus on radiation sensitizers aligns with the industry's trend of exploring combination therapies to enhance the effectiveness of radiation treatment.
• The Phase 2 trial design, including randomization and dose optimization, is consistent with standard clinical trial practices.
• The company's target patient population, IDH wild-type, methylation negative glioblastoma, is a specific and challenging area of oncology research.
• Other companies such as Karyopharm Therapeutics and Oncoceutics are also developing novel therapies for glioblastoma, but Shuttle Pharma's approach with a radiation sensitizer is a distinct strategy.
• The estimated 18-24 month timeline for the trial is within the typical range for Phase 2 clinical trials in oncology.

Stakeholder Impact

• Shareholders may view the progress of the clinical trial positively.
• Patients with glioblastoma may benefit from the development of new treatment options.
• The medical community may gain valuable insights from the trial results.

Next Steps

• The company will continue to screen and enroll patients in the Phase 2 clinical trial.
• The company will monitor the trial progress and analyze the data to determine the optimal dose of Ropidoxuridine.
• The company will complete the trial over the next 18 to 24 months.

Key Dates

Keywords

Ropidoxuridine, Glioblastoma, Clinical Trial, Radiation Therapy, Orphan Drug Designation, Cancer Treatment, Phase 2 Trial, Radiation Sensitizer